PL2370096T3 - Kombinacje przeciwnowotworowe zawierające cytarabinę i przeciwciała specyficznie rozpoznające CD38 - Google Patents

Kombinacje przeciwnowotworowe zawierające cytarabinę i przeciwciała specyficznie rozpoznające CD38

Info

Publication number
PL2370096T3
PL2370096T3 PL09775304T PL09775304T PL2370096T3 PL 2370096 T3 PL2370096 T3 PL 2370096T3 PL 09775304 T PL09775304 T PL 09775304T PL 09775304 T PL09775304 T PL 09775304T PL 2370096 T3 PL2370096 T3 PL 2370096T3
Authority
PL
Poland
Prior art keywords
antibodies recognizing
combinations containing
recognizing specifically
antitumor combinations
containing cytarabine
Prior art date
Application number
PL09775304T
Other languages
English (en)
Inventor
Pascale Lejeune
Patricia Vrignaud
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40627502&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2370096(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of PL2370096T3 publication Critical patent/PL2370096T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
PL09775304T 2008-11-28 2009-11-27 Kombinacje przeciwnowotworowe zawierające cytarabinę i przeciwciała specyficznie rozpoznające CD38 PL2370096T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08291118A EP2191842A1 (en) 2008-11-28 2008-11-28 Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine
PCT/IB2009/055391 WO2010061359A1 (en) 2008-11-28 2009-11-27 Antitumor combinations containing antibodies recognizing specifically cd38 and cytarabine
EP09775304.0A EP2370096B1 (en) 2008-11-28 2009-11-27 Antitumor combinations containing cytarabine and antibodies recognizing specifically cd38

Publications (1)

Publication Number Publication Date
PL2370096T3 true PL2370096T3 (pl) 2017-10-31

Family

ID=40627502

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09775304T PL2370096T3 (pl) 2008-11-28 2009-11-27 Kombinacje przeciwnowotworowe zawierające cytarabinę i przeciwciała specyficznie rozpoznające CD38

Country Status (38)

Country Link
US (1) US20120093806A1 (pl)
EP (2) EP2191842A1 (pl)
JP (2) JP2012510463A (pl)
KR (1) KR101715958B1 (pl)
CN (2) CN107096022A (pl)
AR (1) AR073425A1 (pl)
AU (1) AU2009321251B2 (pl)
BR (1) BRPI0921858B1 (pl)
CA (1) CA2745005C (pl)
CL (1) CL2011001232A1 (pl)
CO (1) CO6440556A2 (pl)
CR (1) CR20110282A (pl)
DK (1) DK2370096T5 (pl)
EA (1) EA027070B1 (pl)
EC (1) ECSP11011071A (pl)
ES (1) ES2638926T3 (pl)
HN (1) HN2011001423A (pl)
HR (1) HRP20171301T1 (pl)
HU (1) HUE035910T2 (pl)
IL (2) IL213115A (pl)
LT (1) LT2370096T (pl)
MA (1) MA32899B1 (pl)
MX (1) MX344973B (pl)
NI (1) NI201100107A (pl)
NZ (1) NZ593085A (pl)
PA (1) PA8849901A1 (pl)
PE (1) PE20120205A1 (pl)
PL (1) PL2370096T3 (pl)
PT (1) PT2370096T (pl)
RS (1) RS56248B1 (pl)
SG (1) SG171821A1 (pl)
SI (1) SI2370096T1 (pl)
TN (1) TN2011000242A1 (pl)
TW (1) TWI436770B (pl)
UA (1) UA104160C2 (pl)
UY (1) UY32266A (pl)
WO (1) WO2010061359A1 (pl)
ZA (1) ZA201104064B (pl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2191842A1 (en) * 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine
ES2617446T3 (es) 2010-09-27 2017-06-19 Morphosys Ag Anticuerpo anti-cd38 y lenalidomida o bortezomib para el tratamiento del mieloma múltiple y nhl
UA112170C2 (uk) * 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
US9579378B2 (en) 2012-09-25 2017-02-28 Morphosys Ag Combinations and uses thereof
WO2014159911A1 (en) * 2013-03-13 2014-10-02 Sanofi Compositions comprising anti-cd38 antibodies and carfilzomib
TN2016000142A1 (en) 2013-10-31 2017-10-06 Sanofi Sa Specific anti-cd38 antibodies for treating human cancers.
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
MX2017003115A (es) 2014-09-09 2017-11-17 Janssen Biotech Inc Terapias de combinacion con anticuerpos anti-cd38.
CN107406506A (zh) 2014-12-04 2017-11-28 詹森生物科技公司 用于治疗急性髓系白血病的抗cd38抗体
JP6827426B2 (ja) 2015-05-20 2021-02-10 ヤンセン バイオテツク，インコーポレーテツド 軽鎖アミロイドーシス及びその他のｃｄ３８陽性血液悪性疾患の治療のための抗ｃｄ３８抗体
AU2016282674B2 (en) 2015-06-22 2022-01-13 Janssen Biotech, Inc. Combination therapies for heme malignancies with anti-CD38 antibodies and survivin inhibitors
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
US10746739B2 (en) * 2015-09-14 2020-08-18 Leukemia Therapeutics, LLC Identification of novel diagnostics and therapeutics by modulating RhoH
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
LT3827845T (lt) 2015-11-03 2022-06-10 Janssen Biotech, Inc. Poodinės anti-cd38 antikūnų kompozicijos ir jų naudojimas
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
US11618787B2 (en) 2017-10-31 2023-04-04 Janssen Biotech, Inc. Methods of treating high risk multiple myeloma
JP2022524204A (ja) 2019-03-15 2022-04-28 モルフォシス・アーゲー 自己抗体介在性自己免疫疾患の処置のための、抗ｃｄ３８抗体及びその医薬組成物
US11655302B2 (en) 2019-06-10 2023-05-23 Sanofi Anti-CD38 antibodies and formulations
CN112876563B (zh) * 2019-11-29 2022-08-16 康诺亚生物医药科技（成都）有限公司 药物组合物及其制备方法和应用
CN115698064A (zh) 2019-12-05 2023-02-03 赛诺菲-安万特美国有限责任公司 用于皮下施用的抗cd38抗体的配制品
TW202235435A (zh) 2021-01-14 2022-09-16 德商莫菲西斯公司 抗cd38抗體及其用途
TW202302642A (zh) 2021-03-01 2023-01-16 德商莫菲西斯公司 用於治療抗體介導移植物排斥用途之抗ｃｄ３８抗體
CN113278075B (zh) * 2021-06-18 2021-12-14 芜湖森爱驰生物科技有限公司 一种炎症检测试剂盒
TW202321303A (zh) 2021-07-19 2023-06-01 德商莫菲西斯公司 抗pla2r自體抗體媒介膜性腎病變之治療

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
SG48759A1 (en) 1990-01-12 2002-07-23 Abgenix Inc Generation of xenogenic antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP2305027B1 (en) 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
ATE200679T1 (de) 1997-04-14 2001-05-15 Micromet Ag Neues verfahren zur herstellung von anti-humanen antigenrezeptoren und deren verwendungen
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
JP2003524587A (ja) * 1998-06-05 2003-08-19 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ 多発性骨髄腫を処置するための、ｃｄ３８に対する、遺伝子操作した抗体の使用
US20080057070A1 (en) * 2004-11-04 2008-03-06 Chiron Corporation Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use
EA015584B1 (ru) * 2005-03-23 2011-10-31 Генмаб А/С Антитело к cd38 человека и его применение
NZ576122A (en) * 2006-09-26 2012-09-28 Genmab As Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
AU2009206506B2 (en) * 2008-01-23 2013-01-10 Xencor, Inc. Optimized CD40 antibodies and methods of using the same
EP2191842A1 (en) * 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine

Also Published As

Publication number Publication date
AU2009321251A1 (en) 2010-06-03
PT2370096T (pt) 2017-09-08
HN2011001423A (es) 2014-01-13
ES2638926T3 (es) 2017-10-24
IL213118A (en) 2017-08-31
PE20120205A1 (es) 2012-03-03
JP6072854B2 (ja) 2017-02-01
LT2370096T (lt) 2017-09-25
NI201100107A (es) 2011-09-26
IL213115A (en) 2017-08-31
IL213118A0 (en) 2011-07-31
SI2370096T1 (sl) 2017-10-30
CR20110282A (es) 2011-09-20
CN107096022A (zh) 2017-08-29
HRP20171301T1 (hr) 2017-10-20
CL2011001232A1 (es) 2012-02-10
DK2370096T3 (en) 2017-07-17
ECSP11011071A (es) 2011-07-29
US20120093806A1 (en) 2012-04-19
KR20110096551A (ko) 2011-08-30
MA32899B1 (fr) 2011-12-01
NZ593085A (en) 2012-12-21
DK2370096T5 (en) 2017-09-18
EP2191842A1 (en) 2010-06-02
CA2745005C (en) 2020-08-11
EP2370096A1 (en) 2011-10-05
UY32266A (es) 2010-06-30
KR101715958B1 (ko) 2017-03-14
RS56248B1 (sr) 2017-11-30
TWI436770B (zh) 2014-05-11
TN2011000242A1 (en) 2012-12-17
EA027070B1 (ru) 2017-06-30
HUE035910T2 (en) 2018-05-28
MX2011005666A (es) 2011-09-30
UA104160C2 (uk) 2014-01-10
CN102264386A (zh) 2011-11-30
TW201023863A (en) 2010-07-01
AR073425A1 (es) 2010-11-03
PA8849901A1 (es) 2010-07-27
CO6440556A2 (es) 2012-05-15
BRPI0921858B1 (pt) 2022-11-16
JP2012510463A (ja) 2012-05-10
AU2009321251B2 (en) 2016-06-09
WO2010061359A1 (en) 2010-06-03
MX344973B (es) 2017-01-12
ZA201104064B (en) 2012-09-26
IL213115A0 (en) 2011-07-31
SG171821A1 (en) 2011-07-28
EA201100868A1 (ru) 2011-10-31
EP2370096B1 (en) 2017-05-31
CA2745005A1 (en) 2010-06-03
BRPI0921858A2 (pt) 2018-10-09
JP2015205893A (ja) 2015-11-19

Similar Documents

Publication Publication Date Title
ZA201104064B (en) Antitumor combinations containing antibodies recognizing specifically cd38 and cytarabine
HK1164165A1 (en) Antitumor combinations containing antibodies recognizing specifically cd38 and melphalan cd38
HK1164154A1 (en) Antitumor combinations containing antibodies recognizing specifically cd38 and cylophosphamide cd38
HK1164153A1 (en) Antitumor combinations containing antibodies recognizing specifically cd38 and vincristine cd38
HRP20181787T1 (hr) Antitumorske kombinacije koje sadržavaju protutijela koja specifično prepoznaju cd38 i bortezomib
GB2468261B (en) Enhanced note processing
IL209309A0 (en) Anti-fn14 antibodies and uses thereof
IL216731A (en) And antibodies against p95 – her2 and their uses
EP2207803A4 (en) CD9-SPECIFIC HUMAN ANTIBODIES
GB0807018D0 (en) Antibodies and treatment
HK1146922A1 (en) Pencil
GB0803749D0 (en) Mouthpiece
HRP20190159T1 (hr) Antitijela humanog anti-alfa-sinukleina
GB0815918D0 (en) Pocket tops
TWM347415U (en) Band recognition structure
GB0818335D0 (en) Curl pearl
GB0801776D0 (en) Amusement rides